Milestone Pharmaceuticals Inc. Payments of Debt Issuance Costs
Milestone Pharmaceuticals Inc. (MIST) reported Payments of Debt Issuance Costs of $2.78 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-03-13
- Milestone Pharmaceuticals Inc. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00.
- Milestone Pharmaceuticals Inc. payments of debt issuance costs for the quarter ending 2023-09-30 was $0.00.
- Milestone Pharmaceuticals Inc. payments of debt issuance costs for fiscal 2023 was $2.78M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $2.78M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.78M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $2.78M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |